Abstract
The research for the identification and development of new drugs represents a very complex process implying long times and massive investments. This process was not able to parallel the rate of discoveries made in the field of genomic and molecular biology and a gap created between demand of new drugs and the ability of pharmaceutical companies to select good candidates. Positron Emission Tomography, among the different Molecular Imaging modalities, could represent a new tool for the early assessment and screening of new drug candidates and, due to its physical performances and the characteristics of positron-labeled tracers, gain the role of “Biomarker” accepted by the Companies and the Regulatory Bodies of Drug Agencies. To fulfil this task PET has to exploit all of its special features such as data absolute quantification and modelling, high spatial resolution and dynamic imaging. Relevant efforts need to be directed to the careful design and validation of experimental protocols with the main goal of achieving consistency in multi- centric trials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
JM Collins, Imaging and other Biomarkers in early clinical studies: One step at a time or re-engineering drug development, J. Clin. Oncol., 2005; 23(24): 5417–5419.
S Ekins, Y Nikolosky, T Nikolskaya, Application of Systems biology to absorption, distribution, metabolism, excretion and toxicity, Trends Pharmacol. Sci., 2005; 26(4):202–209.
DH Townsend, T Bayer, TM Blodgett, PET/CT scanners: a hardware approach to image fusion, Seminars Nucl. Med. 2003: 193–204. PE Kinahan, BH Hasegawa, and T Beyer, X-ray Based Attenuation Correction for PET/CT, ibid. 166–179.
I Sachelarie, K Kerr et al., Integrated PET-CT: evidence-based review of oncology indications, Oncology (Williston Park). 2005;19(4):481–90; discussion 490–2, 495–6.
GB Saha, Basics of PET Imaging: Physics, Chemistry, and Regulations; Springer Verlag, New York, 2005.
ME Phelps, PET Molecular imaging and its biological applications, Springer Verlag, New York, 2004.
SA Nehmeh, YE Erdi, et al., Four-dimensional (4D) PET/CT imaging of the thorax Med Phys. 2004; 31(12): 3179–86.
P Iozzo, A Gastaldelli, et al., 18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study, J Nucl Med. 2006; 47(6):1016–22.
SS Gambhir, J Czernin, et al. A tabulated summary of FDG PET literature, J.Nucl.Med. 2001; 42(suppl.5):1S–93S.
SM Larson, LH Swartz, 18F-FDG PET as a candidate for “qualified biomarker”: Functional assessment of treatment response in oncology, J.Nucl.Med., 2006; 47:901–903.
LK Shankar, JM Hoffman et al., Guidelines for the use of 18F-FDG PET as an indicator of therapeutic response in patients in national Cancer Institute trials, J.Nucl.Med., 2006; 47: 1059–1066.
M Rudin, R Weissleder, Molecular imaging in drug discovery and development. Nature Rev Drug Disc. 2003;2:123–131.
SR Cherry. Use of positron emission tomography in animal research. ILAR J. 2001;42: 219–232.
SR Cherry, In vivo molecular and genomic imaging: new challenges for imaging physics, Phys. Med. Biol., 2004; 49:R13–R48.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer
About this paper
Cite this paper
SALVADORI, P.A. (2007). POSITRON EMISSION TOMOGRAPHY APPLICATION TO DRUG DEVELOPMENT AND RESEARCH. In: Lemoigne, Y., Caner, A., Rahal, G. (eds) Physics for Medical Imaging Applications. NATO Science Series, vol 240. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5653-6_26
Download citation
DOI: https://doi.org/10.1007/978-1-4020-5653-6_26
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-5649-9
Online ISBN: 978-1-4020-5653-6
eBook Packages: Physics and AstronomyPhysics and Astronomy (R0)